Sarcomas, a diverse group of malignancies, exhibit substantial heterogeneity in both biological behavior and microenvironment, influencing their response to immunotherapy. Although pembrolizumab is ...

Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22+ Philadelphia Chromosome–Negative B-Cell Precursor Acute Lymphoblastic Leukemia We enrolled 16 patients ...

Poly (ADP-ribose) Polymerase Inhibitor Resistance Driven by Emergence of Polyclonal Mutations With Convergent Evolution: A Molecular Tumor Board Discussion The following represents disclosure ...

Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial At the time of data lock, 204 ...

Improving vaccination counseling rates in first time patients with cancer: A multi-disciplinary approach. This is an ASCO Meeting Abstract from the 2024 ASCO Quality Care Symposium. This abstract does ...

*Ambulatory visits days are not mutually exclusive. This is an ASCO Meeting Abstract from the 2024 ASCO Quality Care Symposium. This abstract does not include a full text component.

Association of Participation in Medicare's Oncology Care Model With Spending, Utilization, and Quality Outcomes Among Commercially Insured and Medicare Advantage Members In this multicenter phase I ...

Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment 18F-Fluorodeoxyglucose ...

Discordance Between the Initial Diagnosis of Sarcomas and Subsequent Histopathological Revision and Molecular Analyses in a Sarcoma Reference Center in Brazil This study involved 3,708 patients with ...

Impact of the Affordable Care Act and Medicaid Expansion Among Patients With HIV-Associated Aggressive B-Cell Non-Hodgkin Lymphomas ...

Smartwatch Biometrics in the Electronic Medical Record: Time for a New Vital Sign? Before this clinical optimization process can start, the new first-in-class drug needs to be developed and approved.